23 May 2013 12:29
FOR IMMEDIATE RELEASE 23 MAY 2013
ANNUAL GENERAL MEETING: 2013
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
As part of the formal proceedings Dimitri Dimitriou, Chief Executive Officer, made the following statement:
"This week we were delighted to announce that we had secured a £50 million financing facility for our lead compound Lupuzor, underwritten by Henderson Global's Subsidary Darwin Strategic ("Darwin"). This commitment from Darwin allows ImmuPharma to complete the last development stage, Phase III, of Lupuzor putting us in a much stronger negotiating position with potential licensing partners for a corporate deal. We look forward to providing more news in the near future regarding the development plans of Lupuzor.
In addition to Lupuzor, our second lead compound for cancer, IPP-204106 is in its second trial in cancer patients. If data are promising, this may create a further opportunity for a corporate collaboration.
In closing, the Board would like to thank both its shareholders as well as its scientific advisors the Centre Nationale de la Recherche Scientifique in France for their continued support."
For further information please see the Group's web site, www.immupharma.com, or contact:
ImmuPharma PLC | +44 20 7152 4080 |
Richard Warr, Chairman | |
Dimitri Dimitriou, Chief Executive Officer Tracy Weimar, VP Operations and Finance | |
Lisa Baderoon, Head of Investor Relations | +44 7721 413 496 |
Panmure Gordon | +44 20 7886 2500 |
Hugh Morgan, Fred Walsh, Hannah Woodley |
Immupharma (IMM)